Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03755726
Recruiting Observational

A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort

NCT03755726 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de PAU
Phase
Observational
Started
2019-09-20
Last updated
2026-03-23

Condition(s) studied

Malignant Hypertension

Study summary

This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. The network that will emerge will finally lead to the opportunity of setting up therapeutic trials and establishing recommendations based on solid scientific evidence.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Malignant hypertension according to the classic definition (Severe hypertension, above 180/110 associated with severe hypertensive retinopathy) * Severe hypertension (above 180/110) associated with acute damage of 3 target organ due to high blood pressure Exclusion Criteria: * Age \< 18 years old * Patients who cannot freely give their consent, or patients who refuse to participate * Dialysis

Primary outcome measure(s)

  • prognosis — 5 years
    5-year prognosis for patients with malignant hypertension

Trial sites (37)

FacilityCityRegionStatus
CH d'Annecy Annecy France Recruiting
CH de la côte Basque Bayonne France Recruiting
Avicenne APHP Bobigny France Recruiting
CHU - Hôpital St André Bordeaux France Recruiting
CH de Chalon sur Saone Chalon-sur-Saône France Recruiting
CH Métropole Chambéry France Recruiting
CHU de Clermont FERRAND Clermont-Ferrand France Recruiting
Hôpital Henri Mondor Créteil France Recruiting
CH de Dinard Dinard France Recruiting
CHU Michallon Grenoble France Recruiting
hôpital de Haguenau Haguenau France Recruiting
Pôle Santé Sud Le Mans France Recruiting
CH de Libourne Libourne France Recruiting
CHRU de Lille Lille France Recruiting
Clinique Vert Coteau Marseille France Recruiting
Hopital de la conception Marseille France Recruiting
CH Martigues Martigues France Recruiting
CHU de Montellier Montpellier France Recruiting
CHU - Hôpital Laennec Nantes France Recruiting
Hôpital Saint Joseph Paris France Recruiting
Hôpital Européen Georges Pompidou Paris France Recruiting
APHP Bichat Paris France Recruiting
Fondation Adolphe de Rothschild Paris France Recruiting
Hôpital Tenon Paris France Recruiting
CH de PAU Pau France Recruiting
CHU de Pointe à Pitre Pitres France Not Yet Recruiting
CHU de Poitiers Poitiers France Recruiting
CHU de Rennes Rennes France Recruiting
CHU de ROUEN Rouen France Recruiting
Clinique sainte Clotilde Saint-Denis France Recruiting
CHU de St Etienne Saint-Etienne France Recruiting
CH de St Nazaire Saint-Nazaire France Recruiting
CHU de Strasbourg Strasbourg France Recruiting
CHU de Toulouse Rangueil Toulouse France Recruiting
CHU de Tours Tours France Recruiting
CH de Valenciennes Valenciennes France Recruiting
National Institute of Cardiology Warsaw Poland Not Yet Recruiting

More Centre Hospitalier de PAU trials in France

3-hour Versus 12-hour Double-balloon Catheter for Labor Induction Starting soon
Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia Active, not recruiting
Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank Recruiting

Other trials for the same condition

Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03755726 on ClinicalTrials.gov ↗ ← All trials in France